Immunogenic death of colon cancer cells treated with oxaliplatin

By A. Tesnière, F. Schlemmer, V. Boige, Oliver Kepp, Isabelle Martins, François Ghiringhelli, L. Aymeric, M. Michaud, L. Apetoh, L. Barault and 8 more. Oncogene, 2010

1,108 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/9004ea1b9be84364617e2b413b72cdf185ae47e5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Zitvogel
3. L. Galluzzi
4. M. Smyth
5. Oliver Kepp
6. S. Formenti
7. S. Demaria
8. A. Buqué

In Oncology

1. Guido Kroemer
2. L. Zitvogel
3. L. Galluzzi
4. S. Formenti
5. S. Demaria
6. Oliver Kepp
7. M. Smyth
8. J. Wolchok

Citations in the corpus

• Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013, background): “Whereas oxaliplatin can trigger an ER stress response leading to CRT exposure independently from its effects on nuclear DNA (Panaretakis et al., 2009), cisplatin is a relatively weak inducer of ER stress (Tesniere et al., 2010).”
• Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, positive): “Oxa treatment induces immunogenic CT26 tumor cell death (Apetoh et al., 2007; Tesniere et al., 2010) and increases (A) Tumor size measurement of MCA205 fibrosarcoma-bearing C57BL/6 mice (n = 7–8 per group) treated with PBS or chemotherapy (cisplatin or doxorubicin) together with anti-PD-1 +…”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…(including cisplatin and the alkylating agent melphalan) by combining them with ER-stressing agents like cardiac glycosides (Menger et al., 2012) and pyridoxine (Aranda et al., 2015), or by the intratumoral administration of recombinant CALR (Dudek-Peri c et al., 2015; Tesniere et al., 2010).”
• Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer (2013, background): “stressed cells, (ii) subsequent secretion of ATP and (iii) release of high-mobility group box-1 (HMGB1) and HSPs by dying tumor cells.(1,98) Ecto-CRT favors the engulfment of”
• Molecular mechanisms of cisplatin resistance (2012, background): “In addition, whereas oxaliplatin has recently been shown to induce a type of cell death that is immunogenic (that is, it stimulates a tumor-specific cognate immune response) (Tesniere et al., 2010), cisplatin fails to do so (Obeid et al., 2007; Kepp et al., 2011).”
• Consensus guidelines for the detection of immunogenic cell death (2014, background): “This said, it should be kept in mind that the capacity of a given agent to cause ICD or exacerbate the immunogenicity of apoptosis cannot be predicted yet from its structural or chemical properties, since molecules as similar to each other as oxaliplatin and cisplatin do not share this functional pr”